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ABSTRACT Amber suppressor genes corresponding to
Escherichia coli tRNAfh' and tRNACS have been constructed
for use in amino acid substitution studies as well as protein
engineering. The genes for either tRNAPFhA or tRNACG*A both
with the anticodon 5' CTA 3' were assembled from four to six
oligonucleotides, which were annealed and ligated into a vec-
tor. The suppressor genes are expressed constitutively from a
synthetic promoter, derived from thepromoter sequence of the
E. coli lipoprotein gene. The tRNAI suppressor (tRNAPchuA)
is 54-100% efficient in vivo, while the tRNACYU suppressor(tRNAccUA) is 17-50% efficient. To verify that the suppressors
insert the predicted amino acids, both genes were used to
suppress an amber mutation in a protein coding sequence.
NH2-terminal sequence analysis of the resultant proteins re-
vealed that tRNAP~hueA and tRNA~ccA insert phenylalanine and
cysteine, respectively. To demonstrate the potential of these
suppressors, tRNAPhA and tRNAcIA have been used to effect
amino acid substitutions at specific sites in the E. coli lac
repressor.
Nonsense suppressors are alleles of tRNA genes altered in
the anticodon, resulting in insertion of an amino acid in
response to a termination codon. These suppressors have
been important tools in bacterial genetics (1) as well as in the
study of recognition oftRNA by aminoacyl tRNA synthetase
(2). The use of nonsense suppressors also offers exciting
possibilities for protein engineering, since numerous altered
proteins with known amino acid changes can be generated
easily. By this method, genes containing amber, ochre, or
opal mutations (resulting in UAG, UAA, or UGA chain-
terminating codons, respectively) are expressed in mutant
strains that produce suppressor tRNAs capable of inserting
an amino acid in response to the nonsense mutation. Many
single amino acid substitutions at specified positions in
proteins have already been made. For example, nonsense
suppression has been used to create close to 400 mutant lac
repressor proteins, each carrying a known amino acid re-
placement (3). Unfortunately, the range of amino acid ex-
changes made possible by nonsense suppression has been
limited by the relatively small set of nonsense suppressors
available. Until recently, only five different amino acids
could be inserted at an amber codon by suppressor tRNAs.
The amber suppressor tRNAs that have been generated in
vivo (supD, supE, supF, and supP), insert serine, glutamine,
tyrosine, and leucine, respectively, in response to UAG
codons. In addition, Murgola and coworkers have described
a glycine-inserting amber suppressor derived from a series of
in vivo genetic manipulations (4). [Ochre suppressors oper-
ating at reduced efficiencies can insert additional amino
acids-for instance, supG directs the insertion of lysine at
UAA and UAG codons (5), but the inefficient suppression
greatly limits their utility for generating altered proteins.]
With the exception of the glycine suppressor described by
Murgola, the existing amber suppressor alleles arose from a
single base change, resulting in the anticodon 5' CUA 3',
which recognizes the amber codon 5' UAG 3' (6-10).
Creating new suppressor alleles by standard genetic means is
unlikely, as virtually every other tRNA requires more than a
single base change to yield a CUA anticodon. However,
advances in oligonucleotide synthesis (11) have made possi-
ble the in vitro construction ofnew suppressor tRNAs, which
permits us to greatly extend the utility of this approach. To
expand the available collection of amber suppressors in
Escherichia coli, we have synthesized the genes for several
tRNAs, altering the anticodon to enable recognition ofUAG
(amber) codons. Here we describe the construction of the
genes for two such suppressor tRNAs, which insert phenyl-
alanine and cysteine at high efficiency, and we demonstrate
their utility in amino acid substitution studies ofthe E. coli lac
repressor.
MATERIALS AND METHODS
Bacteria, Bacteriophage, Media, and Reagents. E. coli
strain XAC-1 is F' lacI373lacZ8,,, proB+/F- A(lacproB)X,,i
nalA, rif, argEm, ara. The F1 phage, IR1, was obtained from
E. Meyerowitz. Indicator plates used for transformations
were minimal M9 glucose (12) supplemented with ampicillin
(100 pug/ml) and the indicator dye 5-bromo-4-chloro-3-indolyl
-3-D-galactopyranoside (40 pkg/ml). Folic acid and methotrex-
ate were purchased from Calbiochem and ICN, respectively.
Oligonucleotide Synthesis and Purification. Oligonucleo-
tides were synthesized on an Applied Biosystems 380A DNA
synthesizer. Three to five A260 units of oligonucleotide were
purified by electrophoresis through a 20%o acrylamide/7 M
urea gel, visualized by UV shadowing, excised, and eluted in
0.3 M NaCl/10 mM Tris-HCl, pH 7.4/1 mM EDTA/1%
phenol, at 370C for 18 hr. The DNA was precipitated and
washed with ethanol, dried, and resuspended in distilled
H20.
Gene Synthesis. Each oligonucleotide (2 pug) was phos-
phorylated in 70 mM Tris'HCl, pH 7.6/10 mM MgCl2/5 mM
dithiothreitol/100 .M ATP, with 4 units of polynucleo-
tidekinase for 1 hr at 370C. The phosphorylated oligonucle-
otides (80 pmol each) were mixed together in 100 mM NaCl,
heated to 80'C for 5 min, then allowed to cool to room
temperature over a period of 3 hr. The entire mixture was
combined with vector PGFIB-I (previously cleaved with
EcoRI and Pst I) to give a mass ratio of 10:1 (insert/vector).
Subsequent ligation was carried out in 50 mM Tris-HCl, pH
7.6/10 mM MgCl2/20 mM dithiothreitol/50 mM NaCl/1 mM
ATP/bovine serum albumin (50 ,ug/ml), with 1 unit of T4
Abbreviations: DHFR, dihydrofolate reductase; bp, base pair(s).
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DNA ligase at 15'C for 12 hr. The ligation mixture was used
to transform competent E. coli XAC-1 cells. From purified
colonies exhibiting the suppressor phenotype on indicator
medium, single-stranded DNA was made by using the F1
phage IR1 as a helper (13) and sequenced by the chain-
termination method of Sanger et al. (14).
Protein Purification. Purification of mutant dihydrofolate
reductase (DHFR) protein was carried out by a combination
of the methods of Baccanari et al. (15-17) and is briefly
described here. E. coli XAC-1 carrying plasmid pDa3-12:Phe
was cultured in 6 liters of minimal M9 glucose medium
supplemented with ampicillin (50 ,tg/ml) at 370C with aera-
tion for 18 hr. Cells were harvested and lysed (15) and the
crude lysate was extracted with ammonium sulfate to 90%
saturation (16). The precipitate was brought to a protein
concentration of 20 mg/ml, 3.2 ml of methotrexate Sepharose
was added, and the mixture was dialyzed for 18 hr (16). The
resin was batch-washed (17) and the DHFR was eluted with
folic acid (17). At this point, the DHFR was 99% pure as
judged by silver staining (18) of sodium dodecyl sulfate/poly-
acrylamide gels (19). To remove folate and nucleic acid, peak
fractions were first dialyzed against 50 mM potassium phos-
phate, pH 8.0/1 mM dithiothreitol, and then applied to a
DEAE-Sephacel (Pharmacia) column (protein, 1 ml/mg)
equilibrated with the same buffer. DHFR was eluted in a
linear gradient of 0-0.4 M KCl in 50 mM potassium phos-
phate, pH 8.0/1 mM dithiothreitol. Peak fractions were
pooled, dialyzed against water, and lyophilized.
Protein Sequencing. Mutant DHFR protein was sequenced
on an Applied Biosystems Model 470A gas-phase protein
sequenator (20) by the USC Microchemical Core Laboratory.
Mutant ,3galactosidase was purified (21) and sequenced by
A. Fowler (University of California at Los Angeles).
RESULTS
Gene Construction. The sequences of E. coli tRNAPhA and
tRNAEVA with the alterations necessary to convert them to
amber suppressor tRNAs are shown in Fig. 1. The synthetic
genes for tRNAhA and tRNAcCA are depicted in Fig. 2.
Each gene is constructed from a set of 4-6 complementary
oligonucleotides ranging in size from 23 to 46 nucleotides,
with 7-base-pair (bp) overlaps at the junctions. Each tRNA
gene sequence is flanked at the 5' and 3' ends by EcoRI and
Pst I restriction endonuclease site cohesive ends, respective-
ly. Since the E. coli cellular nucleases that process tRNA
precursors recognize conserved structural elements within
the tRNA and not surrounding sequences (25), we expected
that these constructs would produce fully processed func-
tional tRNAs.
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FIG. 1. RNA sequences of E. coli tRNAgA (22) and tRNAeA
(23) with the base changes that would enable the tRNAs to recognize
amber codons.
The oligonucleotides were annealed and ligated into the
EcoRI/Pst I sites of plasmid pGFIB-I as described in Mate-
rials and Methods. In this vector (Fig. 3), the tRNA gene is
expressed constitutively from a strong synthetic promoter,
based on the promoter sequence of the E. coli lipoprotein
gene lpp (26). Distal to the promoter and restriction site
polylinker is a transcription terminator, which we have
synthesized based on the termination sequence of the ribo-
somal RNA operon rrnC (27-28). Plasmid pGFIB-I also
carries the F1 intergenic region, which in the presence of F1
helper phage allows the production of single-stranded DNA
(13), thus facilitating dideoxy sequencing of the synthetic
gene.
To clone active suppressors, the ligation mixtures
pGFIB:Phe and pGFIB:Cys were transformed into E. coli
strain XAC-1. This strain carries an F' lacproB episome with
an amber mutation early in the lacZ gene. In an Su- strain,
virtually no active p-galactosidase (the Z gene product) is
formed. Suppression of the amber mutation should yield
functional /3galactosidase, resulting in blue colonies on
medium containing the indicator 5-bromo-4-chloro-3-indolyl
f3-D-galactopyranoside. When XAC-1 was transformed with
either pGFIB:Phe or pGFIB:Cys, on average, 60% of the
transformants were blue. To confirm that this phenotype was
plasmid encoded and not due to spontaneous reversion of the
amber mutation, plasmid DNA was isolated from blue colo-
nies and used to retransform XAC-1. Subsequently, single-
stranded DNA was isolated from transformants that gave
blue colonies and sequenced to ensure that there were no
sequence anomalies in the synthetic construct.
Determination of Suppression Efficiency. We have exploit-
ed the properties of a lacI-Z fusion system to measure the
efficiency of suppression. In this system, the lacd and Zgenes
are fused, resulting in a hybrid protein with full 8-galac-
tosidase activity (29). The NH2-terminal, I-encoded portion
of the fusion is not required for f3galactosidase activity,
although continued transcription and translation through this
portion of the fusion is necessary. Thus, the introduction of
nonsense mutations that interrupt translation of the I portion
of the message results in negligible ,B3galactosidase synthesis,
while suppression of these nonsense mutations restores
P-galactosidase synthesis. As 83-galactosidase activity is
independent of the nature of the amino acid being inserted
into the I-encoded portion of the hybrid protein and depen-
dent only on the degree of transmission through the transla-
tion block, the level of fgalactosidase activity is a direct
measure of the efficiency of suppression. Fig. 4 depicts this
fusion system. Previous studies of suppression at different
nonsense sites have shown that the efficiency of suppression
is dependent on the sequence immediately surrounding the
nonsense site; the two bases 3' to the nonsense site are
especially important (29, 30). Generally, amber codons fol-
lowed by an A or G are suppressed more efficiently than
those followed by a C or U, although codons followed by the
sequence CU are well-suppressed.
We have examined tRNAhu1A and tRNAcjA against a set
of ambers in the lacI-Z fusion by assaying 83-galactosidase
activity of the suppressed fusion protein (12). Table 1 shows
the relative efficiency of the new suppressors as well as those
for other suppressors. tRNAhUA has a suppression efficiency
of 54-100%, while the efficiency of tRNAcVA ranges from
17% to 50%, depending on the context of the amber codon.
Determination of Suppressor Specificity. A single change in
the anticodon ofE. coli tRNATrP results in mischarging by the
glutamine aminoacyl tRNA synthetase (31). Similarly, alter-
ation of the anticodon ofE. coli tRNAfmt results in mischarg-
ing by glutamine synthetase (32-34). Given these precedents,
we designed an assay to show directly that the new suppres-
sors actually insert the predicted amino acid. tRNAPCIUA and
tRNAcUA were each used to suppress an amber mutation in
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tRNAPheCUA
EcoRI
5' . IAATTCGCCCGGATAGCTCAGTCGGTAGAGCAGGGGATTCTAAATCCCGTGTCCTTGGTTCGATTCCGAGTICGGGCACTGCAPst I
GCGGGCCTATCGAGTCAGCCATCTCGTCCCCTAAGATTTAGGGGCACAGGAACCAAGCTAAGGCTCAGGCCCGTGt 51
tRNACYSCUA
AATTCGGCGCGTTAACAAAGCGGTTATGTAGCGGATTCTAAATCCGTCTAGTCCGGTTCGACTCCGGAACGCGCCTCCACTGCA
EcoRi GCCGCGCAATTGTTTCGCCAATACATCGCCTAAGATTTAGGCAGATCAGIGCCAAGCTGAGGCCTTGCGCGGAGGTG 5'
Pst I
FIG. 2. Synthetic genes for tRNAEuA and tRNACSA. The first and last nucleotides encoding each tRNA (indicated by a dot) are immediately
flanked by the cohesive ends ofEcoRI and Pst I restriction endonuclease sites, respectively. Arrows indicate the oligonucleotide junctions, and
the altered anticodon is underlined. Note that the tRNApuA gene does not encode the 3'-terminal C and A residues. These residues are added
in vivo by tRNA nucleotidyltransferase (24).
a protein-coding sequence. The resulting altered proteins
were subsequently isolated and subjected to NH2-terminal
sequence analysis to determine which amino acid(s) had been
inserted in response to the amber codon.
For determination of the specificity of tRNAIA, we
constructed an amber mutation via oligonucleotide-directed
mutagenesis, in the 10th residue (valine) ofthe E. colifol gene
encoding DHFR (35) (Fig. 5). DHFR was chosen because it
can be purified in virtually one step by methotrexate affinity
chromatography. Furthermore, the structure of DHFR has
been well-delineated by x-ray crystallography (39-41). The
tenth residue of this protein is not highly conserved through-
out phyla and is not in close proximity to the active site.
Hence, we predicted that substitutions at this site would not
0
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2
Pv1
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lipoprotein promoter
Nor I Nor I
significantly alter the protein's activity or its behavior during
purification. We also converted the 11th residue from Asp to
Asn. The purpose of this GAT -- AAT conversion was to
provide a better context for the amber mutation. Subsequent-
ly, we constructed a plasmid (pDa3-12:Phe) that carries both
thefol amber gene under the control of the tac promoter (38)
and tRNA1A flanked by the lipoprotein promoter and rrnC
terminator (Fig. 5).
DHFR was isolated from XAC-1 cells harboring this
plasmid and subjected to Edman degradation on an automat-
ed protein sequenator (20). In Fig. 6, the picomolar yields of
phenylthiohydantoin-derivatized phenylalanine, valine,
asparagine, and aspartic acid are plotted versus the residue
number. It should be noted that the wild-type copy of thefol
gene is also present in the host chromosome. Under control
ofthe tac promoter, the plasmid-bornefol gene overproduces
DHFR '100-fold above the level produced from the chro-
mosomal copy. This should result in minimal levels of
Val-Asp at positions 10 and 11 (compared with Phe-Asn) in
the presence of a strong suppressor such as tRNAhueA. The
major amino acid at position 10 is indeed phenylalanine, and
no other amino acids are detected at a significant level,
including valine or glutamine. In other studies, we have been
able to detect 10% insertion of an amino acid at residue 10
(28). Therefore, to our limits of detection, phenylalanine is
the sole amino acid inserted by the new suppressor. Residue
0) Su
b)
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Fic. 3. Plasmid pGFIB-I. This vector is a derivative of
pEMBL8+ (13). We have replaced the lac promoter with a synthet-
ically constructed promoter (J.-M.M. and J.H.M., unpublished
results) based on the promoter sequence of the E. coli lipoprotein
gene 'pp (26). Two complementary oligonucleotides encoding a
transcription termination sequence from the E. coli rrnC operon (27)
have been ligated into the Pst I and HindIII site ofthe polylinker (28).
The oligonucleotides encoding the tRNA genes are ligated into the
EcoRI and Pst I sites of the polylinker.
6-goloctosidase
FIG. 4. Use of IacI-Z fusion strains to measure suppression
efficiency. lacI-Z gene fusions are expressed under the control of the
IQ promoter (a). They can be used to measure the efficiency of
suppression when an amber mutation is present in the I sequence (b).
In the absence of suppression, a truncated polypeptide without
,B-galactosidase activity is produced (b). With suppression, a full-
length polypeptide with P-galactosidase activity is synthesized (c).
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Table 1. Suppression of amber mutations in a lacI-Z fusion
1-Galactosidase activity, % of wild type
Suppressor 021c A30 028c A26 A16 017c 013c
tRNA UA 79 100 78 100 78 54 84
tRNAECA 34 53 50 51 35 17 35
supD 27 54 32 25 21 6 26
supE 15 26 10 11 10 0.8 11
supF 34 67 62 100 43 11 46
supP 72 70 80 100 62 30 58
All assays were carried out at 370C and were determined in
duplicate (12). Values are given as the percentage of the wild-type
fusion in the respective suppressor strains. Values for supD, -E, -F,
and -P are taken from Miller and Albertini (29).
11 is predominantly asparagine, with a trace amount of
aspartic acid. This may be the result of deamidation of
asparagine or due to wild-type background.
The specificity of tRNAcuA was determined by A. Fowler
in a similar fashion (personal communication). The synthetic
tRNAcUA gene was used to suppress an amber mutation
located at residue 17 in the lacZ gene. The resulting /&
galactosidase was purified and subjected to NH2-terminal
sequence analysis. Cysteine is the major amino acid inserted
at this site, and again glutamine is not detected at a significant
level (data not shown). tRNA'huA was also used to suppress
the lacZ amber, and the mutant /3-galactosidase was purified
and sequenced by A. Fowler. The results are similar to those
obtained with the fol amber (data not shown).
Substitutions in the lac Repressor. To demonstrate the
potential of the new suppressors for structure function
studies, we have used them to generate specific amino acid
2 12
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FIG. 6. The picomolar yields of phenylthiohydantoin-derivatized
phenylalanine, valine, asparagine, and aspartic acid have been
plotted versus the residue number for DHFR purified from E. coli
XAC-1 cells carrying pDa3-12:Phe.
replacements in the E. coli lac repressor. The lac repressor
is especially suited to amino acid substitution studies as its
properties are well-understood, its activity is readily assayed,
and a large number ofamber mutations in the repressor gene,
lac, have been generated (42). We have previously described
the use of suppressed nonsense mutations to generate altered
lac repressor molecules (3). Close to 90 different nonsense
sites in the lacI gene have been described, and the ability to
add different amino acids by suppression offers the oppor-
tunity to study a hierarchy ofamino acid substitutions at each
site. Table 2 shows several positions in the repressor that are
particularly sensitive to certain amino acid substitutions.
These data can yield useful information regarding the nature
of the amino acid being inserted by the new suppressors. For
instance, glutamine is the wild-type residue at positions 18
and 248. From Table 2 it is evident that these sites specifically
require glutamine among the amino acids examined so far.
Exchanges at position 18 affect operator binding, and sub-
rrnC terminator
sup tRNA gene
FIG. 5. Construction ofplasmid pDa3-12. Oligonucleotide-direct-
ed mutagenesis (36) was carried out on the E. coli fol gene (35)
encoded by a 1-kilobase fragment contained in the vector M13 mp8
(37). Plasmid pDa3-12:sup tRNA, in this case pDa3-12:Phe, was
constructed by a series of subcloning steps. The 247-bp EcoR1l
HindI11 fragment of pTAC12H (38) containing the tac promoter was
ligated into the EcoRI/HindIII sites of pBR322 to create pTAC10.
Subsequently, the DHFR amber encoded by a 1057-bp HindIR
fragment, was subcloned into the HindIII site of pTAC10, which
yielded pDa3-12. The -350-bp Pvu II fragment from pGFIB:Phe
containing the lipoprotein promoter, tRNA~huA, and the rrnC termi-
nator was ligated into pDa3-12 to yield pDa3-12:Phe.
Table 2. Amino acid substitutions in the lac repressor
Wild-type Replacement by suppression
residue Ser Gln Tyr Leu Phe Cys
Tyr-17 + +
Tyr-47 - - + - +
Tyr-282 - - + + + -
Trp-201 - - + - +
Phe-293 + + s s + s
Gln-18 - + - - -
Gln-248 s + s s s s
+, Normal activity; s, DNA binding activity retained but not
inducibility; -, no activity, presumably because of defects in folding,
aggregation, or DNA binding. Partial activities: ± indicates a less
severe defect than T.
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stitutions at position 248 affect inducer binding (the Is
phenotype). These two sites can be used to determine
whether a suppressor is inserting glutamine. Also, the phen-
ylalanine at position 293 is not easily replaced without
affecting the activity of the protein. Note that the phenylal-
anine-inserting suppressor restores the wild-type character,
reinforcing the protein chemistry results for this suppressor.
In addition, the tyrosines at positions 17, 47, and 282, and the
tryptophan at position 201 are sensitive to substitution. Only
certain hydrophobic amino acids are allowed at positions 201
and 282, and the phenylalanine-inserting suppressor does
restore activity in both cases. None of the previous substi-
tutions for tyrosine at position 47 could restore even partial
activity. However, as can be seen from Table 2, the phen-
ylalanine-inserting suppressor can substitute reasonably
well. Possibly, the ring moiety of the tyrosine is crucial at this
position, and the phenylalanine ring fulfills a similar function.
We note that phenylalanine cannot substitute for tyrosine at
position 17, a residue that has been implicated in operator
binding mediated by hydrogen bonding (43). This would be
expected, since the phenylalanine ring lacks the hydroxyl
side chain of tyrosine that could participate in hydrogen
bonding.
DISCUSSION
Nonsense suppressors can be generated by altering the
anticodon of a tRNA to allow recognition of chain-termi-
nation codons. This approach has already met with success
in several cases via oligonucleotide-directed mutagenesis
(44-47).
We have described the construction of two amber sup-
pressor tRNA genes, tRNACUA and tRNACA, which insert
the predicted amino acid at high frequency. By using the
approach of total gene synthesis, we have been able to
construct these suppressor genes very rapidly. Furthermore,
the manner in which the gene constructs are designed-i.e.,
without their natural 5' and 3' flanking sequences-does not
preclude the synthesis of a functional tRNA. We have
subsequently assembled the genes for several other suppres-
sor tRNAs in an effort to create as large a "bank" of amber
suppressors as possible (unpublished results). One potential
obstacle to creating a complete collection of amber suppres-
sors is the possibility that the anticodon of certain tRNAs is
crucial for recognition by its cognate aminoacyl tRNA
synthetase. We therefore developed an assay that would
enable us to determine whether the anticodon had affected
the specificity of the tRNA in question, by showing directly
which amino acid it inserts into an amber site of a protein
coding sequence. From these protein chemistry studies, it is
evident that the new suppressors insert the original amino
acids, phenylalanine and cysteine, at least to the limits of
detection of the protein sequencing systems. Data from
amino acid replacement studies in the lac repressor, utilizing
tRNAPhUA and tRNACVA, support this conclusion. To extend
the sensitivity of detection beyond the limits of protein
sequencing, genetic systems similar to the one featured in
Table 2 can be developed further.
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